Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ)
CNY 15.52
(-0.83%)
CNY 15.52
(-0.83%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 639.22 Million CNY | 27.27% |
| 2022 | 502.25 Million CNY | 76.67% |
| 2021 | 284.28 Million CNY | 16.32% |
| 2020 | 244.39 Million CNY | -31.35% |
| 2019 | 356.02 Million CNY | 43.97% |
| 2018 | 247.29 Million CNY | 42.38% |
| 2017 | 173.68 Million CNY | 66.61% |
| 2016 | 104.24 Million CNY | 13.51% |
| 2015 | 91.84 Million CNY | -3.14% |
| 2014 | 94.82 Million CNY | 30.28% |
| 2013 | 72.78 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 461.81 Million CNY | 29.96% |
| 2024 Q1 | 355.35 Million CNY | -44.41% |
| 2024 Q3 | 471 Million CNY | 1.99% |
| 2023 Q1 | 579.45 Million CNY | 15.37% |
| 2023 FY | 639.22 Million CNY | 27.27% |
| 2023 Q4 | 639.22 Million CNY | 6.57% |
| 2023 Q2 | 550.03 Million CNY | -5.08% |
| 2023 Q3 | 599.83 Million CNY | 9.05% |
| 2022 Q4 | 502.25 Million CNY | 42.18% |
| 2022 FY | 502.25 Million CNY | 76.67% |
| 2022 Q3 | 353.24 Million CNY | 26.12% |
| 2022 Q1 | 275.45 Million CNY | -3.1% |
| 2022 Q2 | 280.08 Million CNY | 1.68% |
| 2021 Q3 | 281.38 Million CNY | 14.27% |
| 2021 FY | 284.28 Million CNY | 16.32% |
| 2021 Q4 | 284.28 Million CNY | 1.03% |
| 2021 Q2 | 246.25 Million CNY | 18.44% |
| 2021 Q1 | 207.92 Million CNY | -14.92% |
| 2020 FY | 244.39 Million CNY | -31.35% |
| 2020 Q4 | 244.39 Million CNY | -37.7% |
| 2020 Q2 | 391.99 Million CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 Q3 | 392.29 Million CNY | 0.08% |
| 2019 Q4 | 356.02 Million CNY | 0.0% |
| 2019 FY | 356.02 Million CNY | 43.97% |
| 2019 Q1 | - CNY | 0.0% |
| 2018 FY | 247.29 Million CNY | 42.38% |
| 2017 FY | 173.68 Million CNY | 66.61% |
| 2016 FY | 104.24 Million CNY | 13.51% |
| 2015 FY | 91.84 Million CNY | -3.14% |
| 2014 FY | 94.82 Million CNY | 30.28% |
| 2013 FY | 72.78 Million CNY | 0.0% |